Treating Geriatric Polypharmacy by Deintensif...

Idiopathic normal pressure hydrocephalus (iNPH) affects approximately 1% to 4% of adults aged 65 years and older and is associated with gait impairment, cognitive decline, and urinary dysfunction. Author Mark G. Luciano, MD, PhD, from Johns Hopkins University, discusses this and ...  عرض المزيد

Rheumatoid arthritis can affect any synovial joint and cause irreversible damage, but early diagnosis and treatment with DMARDs can reduce inflammation and lower the risk of joint destruction. JAMA Associate Editor David Simel, MD, MHS, is joined by review coauthor Josef Smolen, ...  عرض المزيد

Drs Carol H. Wysham and Medha Munshi discuss type 2 diabetes in older adults, understanding geriatric syndromes and how they impact care, and when to de-escalate treatment. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarti ...  عرض المزيد

In this episode, we discuss the approach to deprescribing for several drugs such as benzodiazepine receptor agonists, cholinesterase inhibitors, memantine, antipsychotics, and antihyperglycemics. Key Concepts Medication appropriateness including indication and risk vs. benefit sh ...  عرض المزيد

On this podcast episode, I finish up my breakdown of the Beers Criteria. I cover the use of sliding-scale insulin and sulfonylureas in geriatric patients. Hypoglycemia is a major concern with both of these diabetes management strategies. PPIs show up on the Beers criteria list as ...  عرض المزيد

Send us a voicemail!Medication-related-harm (MRH) is especially prevalent in older adults due to changing physiology as the body ages, increased frailty, and the incidence of polypharmacy in this patient group. Giovanni Furlan, Worldwide Safety Site Lead for Thessaloniki of Pfize ...  عرض المزيد